Abstract
Background: There are many contradictions about pregnancy and fetal/neonatal outcomes after topical use of timolol alone or timolol in combination with other antiglaucoma medications. Methods: Seventy-five pregnant women exposed to antiglaucoma medications were followed prospectively by phone interviews. 27 women used timolol as monotherapy, 48 women used timolol as a part of multidrug therapy. We selected a control group of 187 healthy pregnant women. Results: Topical use of timolol alone or timolol in combination with other antiglaucoma medications does not influence pregnancy or fetal/neonatal outcomes. Conclusion: Beta-blocker is the first choice treatment for glaucoma in pregnancy but, when necessary, multidrug therapy should not to be excluded.
| Original language | English |
|---|---|
| Pages (from-to) | 3-11 |
| Number of pages | 9 |
| Journal | Current Drug Safety |
| Volume | 13 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Mar 1 2018 |
Fingerprint
Keywords
- Congenital anomalies
- Drugs
- Glaucoma
- Pregnancy
- Prenatal diagnosis
- Teratology Information Service (TIS)
ASJC Scopus subject areas
- Toxicology
- Pharmacology
- Pharmacology (medical)
Cite this
Glaucoma drug therapy in pregnancy : Literature review and teratology information service (TIS) case series. / Pellegrino, Marcella; D’Oria, Luisa; De Luca, Carmen; Chiaradia, Giacomina; Licameli, Angelo; Neri, Caterina; Nucci, Marta; Visconti, Daniela; Caruso, Alessandro; De Santis, Marco.
In: Current Drug Safety, Vol. 13, No. 1, 01.03.2018, p. 3-11.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Glaucoma drug therapy in pregnancy
T2 - Literature review and teratology information service (TIS) case series
AU - Pellegrino, Marcella
AU - D’Oria, Luisa
AU - De Luca, Carmen
AU - Chiaradia, Giacomina
AU - Licameli, Angelo
AU - Neri, Caterina
AU - Nucci, Marta
AU - Visconti, Daniela
AU - Caruso, Alessandro
AU - De Santis, Marco
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Background: There are many contradictions about pregnancy and fetal/neonatal outcomes after topical use of timolol alone or timolol in combination with other antiglaucoma medications. Methods: Seventy-five pregnant women exposed to antiglaucoma medications were followed prospectively by phone interviews. 27 women used timolol as monotherapy, 48 women used timolol as a part of multidrug therapy. We selected a control group of 187 healthy pregnant women. Results: Topical use of timolol alone or timolol in combination with other antiglaucoma medications does not influence pregnancy or fetal/neonatal outcomes. Conclusion: Beta-blocker is the first choice treatment for glaucoma in pregnancy but, when necessary, multidrug therapy should not to be excluded.
AB - Background: There are many contradictions about pregnancy and fetal/neonatal outcomes after topical use of timolol alone or timolol in combination with other antiglaucoma medications. Methods: Seventy-five pregnant women exposed to antiglaucoma medications were followed prospectively by phone interviews. 27 women used timolol as monotherapy, 48 women used timolol as a part of multidrug therapy. We selected a control group of 187 healthy pregnant women. Results: Topical use of timolol alone or timolol in combination with other antiglaucoma medications does not influence pregnancy or fetal/neonatal outcomes. Conclusion: Beta-blocker is the first choice treatment for glaucoma in pregnancy but, when necessary, multidrug therapy should not to be excluded.
KW - Congenital anomalies
KW - Drugs
KW - Glaucoma
KW - Pregnancy
KW - Prenatal diagnosis
KW - Teratology Information Service (TIS)
UR - http://www.scopus.com/inward/record.url?scp=85045985080&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045985080&partnerID=8YFLogxK
U2 - 10.2174/1574886312666171030125804
DO - 10.2174/1574886312666171030125804
M3 - Review article
C2 - 29086700
AN - SCOPUS:85045985080
VL - 13
SP - 3
EP - 11
JO - Current Drug Safety
JF - Current Drug Safety
SN - 1574-8863
IS - 1
ER -